EUVIMEDObjevte EUVIMED
MetaanalyseSystematische ÜbersichtOpen access · CC BY-NC 4.0

Meta‐analysis: Incidence of cirrhosis and hepatocellular carcinoma in patients with Fontan palliation

Asif A Hitawala iD, Harish Gopalakrishna, Maria Mironova, Alicia A Livinski, Elizabeth C Wright, Tacy Downing, Seiji Ito, Stacy D Fisher, Ari M Cedars, Anitha S John, Theo Heller

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17952 ↗

At a glance

Metaanalyse in Alimentary Pharmacology & Therapeutics, 2024. Written by Asif A Hitawala and 10 co-authors. Institution: Liver Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA. Major MEDLINE topics: Fontan Procedure, Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis. Cited 6 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA, National Institutes of Health Library, Office of Research Services in support of the NIH Intramural Research Program, National Institutes of Health, Bethesda,…, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and Aims The Fontan palliation is the final stage of surgery for many children born with univentricular physiology. Almost all Fontan patients develop liver fibrosis which may eventually lead to cirrhosis and hepatocellular carcinoma (HCC). These are important causes of morbidity and mortality in these patients. We performed a systematic review and meta‐analysis to assess the incidence of cirrhosis and HCC in Fontan patients and stratify it based on time since surgery.

Methods

A literature search of seven databases identified 1158 records. Studies reporting the number of cirrhosis and HCC cases in Fontan patients and time since Fontan surgery were included. In the cirrhosis cohort, we included only those studies where all patients underwent liver biopsy.

Results

A total of 23 studies were included: 12 and 13 studies in the cirrhosis and HCC cohorts, respectively, with two studies included in both cohorts. The incidence of cirrhosis was 0.97 per 100 patient‐years (95% CI 0.57–1.63), with the incidence and cumulative incidence ≥20 years post Fontan surgery being 1.61 per 100 patient‐years (95% CI 1.24–2.08) and 32.2% (95% CI 25.8%–39.4%), respectively. The incidence of HCC was 0.12 per 100 patient‐years (95% CI 0.07–0.21), with the incidence and cumulative incidence ≥20 years post Fontan surgery being 0.20 per 100 patient‐years (95% CI 0.12–0.35) and 3.9% (95% CI 2.2%–6.8%), respectively. Only about 70% of patients with HCC (20/28) had underlying cirrhosis.

Conclusion

The incidence of cirrhosis and HCC increases over time, especially at ≥20 years post Fontan surgery. Studies are needed to further identify at‐risk patients in order to streamline surveillance for these highly morbid conditions.

Subjects

MeSH terms (MEDLINE)

Fontan ProcedureCarcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisHumansIncidencePalliative Care

Authors and institutions

  • Liver Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • National Institutes of Health Library, Office of Research Services, Office of the Director, National Institutes of Health, Bethesda, Maryland, USA.
  • Office of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Division of Pediatric Cardiology, Children's National Hospital, Washington, DC, USA.
  • Adult Congenital Heart Disease Center, Johns Hopkins Heart and Vascular Institute, Baltimore, Maryland, USA.
  • Translational Hepatology Section, Liver Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.

ORCID profiles: Asif A Hitawala

Funding

  • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
  • National Institutes of Health Library, Office of Research Services in support of the NIH Intramural Research Program, National Institutes of Health, Bethesda,…
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Hitawala, A. A., Gopalakrishna, H., Mironova, M., Livinski, A. A., Wright, E. C., Downing, T., Ito, S., Fisher, S. D., Cedars, A. M., John, A. S., & Heller, T. (2024). Meta‐analysis: Incidence of cirrhosis and hepatocellular carcinoma in patients with Fontan palliation. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17952

Vancouver

Hitawala AA, Gopalakrishna H, Mironova M, Livinski AA, Wright EC, Downing T, et al. Meta‐analysis: Incidence of cirrhosis and hepatocellular carcinoma in patients with Fontan palliation. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17952

BibTeX
@article{Hitawala2024,
  author = {Hitawala, Asif A and Gopalakrishna, Harish and Mironova, Maria and Livinski, Alicia A and Wright, Elizabeth C and Downing, Tacy and Ito, Seiji and Fisher, Stacy D and Cedars, Ari M and John, Anitha S and Heller, Theo},
  title = {Meta‐analysis: Incidence of cirrhosis and hepatocellular carcinoma in patients with Fontan palliation},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17952}
}
Start for free →